FOMDWebPartPage

Faculty Members

John Mackey

Professor
Medical Oncology
Department of Oncology
University of Alberta
Cross Cancer Institute
11560 University Avenue
Edmonton, Alberta T6G 1Z2
Tel: 780.432.8221

Profile

I direct the Clinical Trial Unit at the Cross Cancer Institute, a highly motivated team of investigators and experience staff that enters nearly 15% of our patients on cancer therapy trials.  As the Co-Chair of Research for the Northern Alberta Breast Cancer Program, I supervise the clinical and research programs for women with breast cancer in the referral area of the Cross Cancer Institute, Edmonton. I am Executive Director of Translational Research in Oncology, a global network of academic investigators carrying out trials of novel anticancer drug treatments. As a medical oncology clinical investigator, my major interest is in the clinical testing of new biological, hormonal, and cytotoxic drugs for the treatment of early stage and advanced disease. I serve on the steering committees of eleven international systemic therapy trials.

Systemic therapy for breast cancer is frequently limited by drug resistance. My translational research program focuses on the study of the molecular mechanisms underlying drug resistance, and explores novel ways to circumvent and modulate these resistance mechanisms. With my collaborators, we are developing tests to predict which patients are most likely to benefit from anticancer therapy, and exploiting novel targets and pathways to improve systemic cancer therapy.
 
My research program is funded by the National Cancer Institute of Canada, the Alberta Cancer Board, the Alberta Cancer Foundation, the Alberta Chapter of the Canadian Breast Cancer Research Alliance, the Canadian Breast Cancer Research Alliance, the Department of Defense, and several industry sponsors. 
 
Research Facilities and Affiliations
 
My primary academic appointment is in the Division of Medical Oncology in the Department of Oncology. I also hold a cross appointment in the Division of Experimental Oncology.
 
Google Scholar Citations
 
Please click on this link for citations, h-index and i10-index

 

Publications

Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, Whellan DJ, O’Conno CM. Safety and Efficacy of Aerobic Training in Patients With Cancer Who Have Heart Failure: An Analysis of the HF –ACTION Randomized Trial. J Clin Oncol. 2014 Jul 7. Pii: JCO.2013.53.5724.
 
Manage DP, Ma, L, Lauzon J, Howell A, Belch AR, Mackey JR, Pilarski LM. Genotyping Single Nucleotide Polymorphisms in Human Genomic DNA with an Automated and Self-Contained Polymerase Chain Reaction Cassette. J Mol Diagn. 2014 Jul 2. Pii: S1525-1578(14)00101-9.
 
Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey JR, Johnston JB, Adamia S, Belch AR, Pilarski LM. Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer. PLoS One. 2014 Jun 20;9(6):e100691.
 
Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014 May 27; 6:253-9.
 
Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Crawford JJ, Mackey JR. Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes. Med Sci Sports Exerc. 2014 Mar 13.
 
Courneya KS, McKenzie D, Gelmon KA, Mackey JR, Reid RD, Yasui Y, Friedenreich CM, Forbes CC, Trinh L, Jespersen D, Cook D, Proulx C, Wooding E, Dolan LB, Segal RJ. A Multicenter Randomized Trial of the Effects of Exercise Dose and Type on Psychosocial Distress in Breast Cancer Patients Undergoing Chemotherapy. Cancer Epidemiol Biomarkers Prev. 2014 Mar 5.
 
Courneya KS, Segal RJ, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Jespersen D, Cook D, Proulx C, Trinh L, Dolan LB, Wooding E, Forbes CC, McKenzie DC. Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: a multicenter randomized trial. Breast Cacner Res Treat. 2014 Feb 20.
 
Khouri MG, Hornsby WE, Risum N, Velazquez EJ, Thomas S, Lane A, Scott JM, Koelwyn GJ, Herndon JE, Mackey JR, Douglas PS, Jones LW. Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat. 2014 Feb; 413(3):531-9.
 
Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Olah A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Buchler MW; for the European Stufy Group for Pancreatic Cancer. Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. J Natl Cancer Inst. 2014 Jan;106(1).
 
Bastani M, Vos L, Asgarian N, Deschenes J, Graham K, Mackey JR, Greiner R. A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status. PLoS One. 2013 Dec 2;8(12):e82144.
 
Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure A, Seguí MA, Tredan O, Antón A, Ramos M, Del Carmen M, Rodríguez-Martín C, Carrasco E, Alba E. Obesity and Survival in Operable Breast Cancer Patients Treated with Adjuvant Anthracyclines and Taxanes According to Pathological Subtypes: A Pooled Analysis. Breast Cancer Res. 2013 Nov 6;15(6):R105.
 
Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Cook D, Jerpersen D, Proulx C, Dolan LB, Forbes CC, Wooding E, Trinh L, Segal RJ. Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Mulicenter Randomized Trial. J Natl Cancer Inst. 2013 Oct 22
 
Hajiloo M, Damavandi B, Hooshsadat M, Sangi F, Mackey JR, Cass CE, Greiner R, Damaraju S. Breast Cancer prediction using genome wide single nucleotide polymorphism data. BMC Bioinformatics. 2013;14 Suppl 13:S3.
 
Cameron D, Brown J, Dent R, Jackisch C, Mackey JR, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Lae R, Im YJ, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant Bevacizumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of Randomized, Phase 3 Trial.  Lancet Oncol. 2013 Sep:14(10):933-42.
 
Aktary Z, Kulak S, Mackey JR, Jahroudi N, Pasdar M. Plakoglobin interacts with the transcription factor p53 and regulates the expression of 14-3-3σ. J Cell Sci. 2013 Jul 15;126(Pt 14).
 
Tang Y, Mackey JR, Lai R, Ghosh S, Santos C, Graham K, Damaraju S, Pasdar M, Li L. Quantitative Proteomic Analysis of HER2 Normal and Overexpressing MCF-7 Breast Cancer Cells Revealed Proteomic Changes Accompanied with HER2 Gene Amplification. J Proteomics. 2013 Jul 11 in press.
 
North S, El-Gehani F, Santos C, Ghosh S, Lai R, Cass CE, Mackey JR. Expression of nucleoside transporters (NT) and deoxycytidine kinase (dCK) proteins in muscle invasive urothelial carcinoma of the bladder (UCCB): correlation with pathologic response to neoadjuvant platinum/gemcitabine combination chemotherapy (NAC). J Urol. 2013 Jul 10.
 
Au HJ, Eiermann W, Robert NJ, Pienkowshi T, Crown J, Martin M, Pawlicki M, Chan A, Mackey JR, Glapsy J, Pinter T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bee V, Santana MJ, Miller DP, Lalla D, Slamon DJ; on behalf of the Translational Research In Oncology in Oncology BCIRG 006 trial investigators. Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab- Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer Results from the BCIRG 006 Study. Oncologist 2013 Jun 28.
 
Sapkota Y, Mackey JR, Lai R, Franco-Villalobos C, Lupichuk S, Robson PJ, Kopciuk K, Cass CE, Yasui Y, Damaraju S.  Assessing SNP-SNP Interactions Among DNA Repair, Modification and Metabolism Related Pathway Gene Breast Cancer Susceptibility.  PLoS One.  2013 Jun 3; 8(6): E64896.
 
Sapkota Y, Yasui Y, Lai R, Sridharan M, Robson PJ, Cass CE, Mackey JR, Damaraju S. Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm. PLoS One. 2013 May 22;8(5):e62550.
 
Hajiloo M, Sapkota Y, Mackey JR, Robson P, Greiner R, Damaraju S. ETHNOPRED: A Novel Machine Learning Method for Accurate Continental and Sub-Continental Ancestry Identification and Population Stratification Correction. BMC Bioinformatics 2013 Feb 22; 14:61
 
Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y,  Mackey JR, Damaraju S. Gremline DNA Copy Number Aberrations Identified as Potential Prognostic Factors for Breast Cancer Recurrence. PLos One. 2013;8(1):e53850. 2013 Jan 16.
 
Scott JM, Lakoski S, Mackey JR, Douglas PS, Haykowsky MJ, Jones LW. The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics. Oncologist. 2013 Jan 18.
 
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Winholes J, Pinter T, Rodriguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; for the TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80